Redeye: Idogen - Could be in for a long period of uncertainty

Idogen has suffered a setback in their pre-clinical work, requiring more evaluation and thus delays in the timelines. The uncertainty has increased significantly and we are adjusting our expectations, arriving at a new fair value range.

Read more and download research update: http://bit.ly/2tcMwWU 

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/